This study looks at how safe and tolerable two drugs, cemsidomide and elranatamab, are when used together for relapsed/refractory multiple myeloma (a type of blood cancer).
In the first part, different doses of cemsidomide with elranatamab will be tested on a few people to find a safe dose. Cemsidomide is taken by mouth for 14 days, then stopped for 14 days (1 cycle = 28 days). Elranatamab is given by injection under the skin twice a month. A steroid called dexamethasone is also given weekly for up to 4 cycles. If the safe dose is found, more people will join to further check safety and any cancer-fighting effects.
- Study involves frequent medication dosing: oral and injectable.
- Participants should have had specific prior treatments for multiple myeloma.
- Cannot join if you have certain other health conditions or recent treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand